Specify a stock or a cryptocurrency in the search bar to get a summary
Shield Therapeutics plc
STXShield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom. Address: Northern Design Centre, Gateshead, United Kingdom, NE8 3DF
Analytics
WallStreet Target Price
1 236.12 GBXP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures STX
Dividend Analytics STX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History STX
Stock Valuation STX
Financials STX
Results | 2019 | Dynamics |